01244 3D MEDICINES-B
3D MEDICINES-B
3D MEDICINES-B
| Listing Date | 2022/12/15 |
| Listing Price | 24.980 |
Subscription Result
- Subscription Rate5.97x
- Guarantee One Lot Size7 lot
- One Lot Success Rate25.01%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
3D Medicines founded in 2014, it is a bio-pharmaceutical company focusing on the research and development of oncology therapies for require long-term care cancer patients. Its core business model is to develop and commercialize oncology products and drug candidates through a combination of co-development, in-licensing and in-house discovery.
--
As of 21 Nov 2022, the Group have built a pipeline consisting of one Core Product and 11 drug candidates, among which, the Core Product envafolimab (brand name: ENWEIDA, 恩維達), as its backbone, was approved in November 2021 and commercialized in December 2021, and seven other drug candidates are in clinical stage.
--
The Group started to generate revenue from the sales of envafolimab to pharmacy operating companies and distributors. Its customers covered 30 provinces and municipalities in China. It has been building its in-house production facilities in Xuzhou, Jiangsu province. It expects to complete building the facilities and commence operation by 2024.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 500 |
GLOBAL OFFERING
| No. of Offer Shares | 16.35M shares |
| No. of International Offer Shares | 14.72M shares |
| No. of HK Offer Shares | 1.64M shares |
| Offer Price | $22.96 - $26.24 |
| Stock Code | 1244 |
| Sponsor(s) | China International Capital Corporation Hong Kong Securities Limited, China Securities (International) Corporate Finance Company Limited |
| Underwriter(s) | China International Capital Corporation Hong Kong Securities Limited, China Securities (International) Corporate Finance Company Limited, CNCB (Hong Kong) Capital Limited, CCB International Capital Limited, Huarong International Securities Limited, Livermore Holdings Limited, ABCI Securities Company Limited, Tiger Brokers (HK) Global Limited, SDHG International Securities Limited, Lego Securities Limited, Valuable Capital Limited, Futu Securities International (Hong Kong) Limited, Victory Securities Company Limited |
TIME TABLE
| Application Period | Nov 29 (Tue) - noon, Dec 07 (Wed) |
| Price Determination Date | Dec 07 (Wed) |
| Result Announcement Date | On or before Dec 14 (Wed) |
| Result Announcement Date | On or before Nov 14 (Mon) |
| Dealings in Shares commence on | Dec 15, 2022. (Thu) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $22.96 - $26.24 |
| Capitalization | 5.87B - 6.71B |
| NAV / share ($) | $5.11 - $5.35 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 24.6, the net proceeds raised would be HKD 245.00M, of which |
| 55% : Used for our Core Product envafolimab |
| 25% : Used for our other drug candidates, including 3D229, 3D011 and 3D185 |
| 10% : Construction of in-house production facilities in Xuzhou, Jiangsu province |
| 10% : Working capital |
IPO NEWS
| 15/12/2022 16:08 |
| {New Stock}3D MEDICINES-B(01244) ends up 25.9% at HK$31.45 |
| 15/12/2022 09:20 |
| {New Stock}3D MEDICINES-B(01244) opens up 16.09% at HK$29 |
| 14/12/2022 18:35 |
| {New Stock}3D MEDICINES-B ends up 15.89% on grey market |
| 14/12/2022 16:20 |
| {New Stock}3D MEDICINES-B(01244) up 1.08% on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).